Skip to main content
Advertising

Originally published August 1, 2014 at 3:37 PM | Page modified August 2, 2014 at 3:24 AM

  • Share:
           
  • Comments
  • Print

Why isn't there a treatment or vaccine for Ebola?

In the four decades since the Ebola virus was first identified in Africa, treatment hasn't changed much. There are no licensed drugs or vaccines for the deadly disease.


AP Medical Writer

Reader Comments
Hide / Show comments
Why do you go there, One? There are a number aides working in Africa that are trying to stop the spread and help (yes,... MORE
Like it or not, drug companies are not charities, and have to make a profit. Developing a new drug can cost many. many... MORE
@One of the Unwashed Masses @NWGuySeattle No, not enough "American" people have been affected to spend "American"... MORE

advertising

LONDON —

In the four decades since the Ebola virus was first identified in Africa, treatment hasn't changed much. There are no licensed drugs or vaccines for the deadly disease.

Some are being developed, but none have been rigorously tested in humans. One experimental treatment, though, was tried this week in an American aid worker sick with Ebola, according to the U.S-based group that she works for in Liberia.

Without a specific treatment, doctors and nurses focus on easing the disease's symptoms -- fever, headache, vomiting and diarrhea -- and on keeping patients hydrated and comfortable.

The outbreak in three West African countries -- Liberia, Guinea and Sierra Leone -- has sickened more than 1,300 people and more than 700 have died since March.

WHY ISN'T THERE A TREATMENT BY NOW?

For one thing, the Ebola virus is hard to work with. The virus doesn't grow well in petri dishes and experiments can only be done in the relatively few labs with the highest security measures.

And while Ebola is lethal, it's rare. Outbreaks are unpredictable, giving doctors few chances to test new treatments. While the current epidemic is the largest recorded, the number of people sickened by Ebola is small compared to the number killed by other diseases like malaria or dengue. Much of the funding for Ebola research is from governments that worry about the virus being used in a bioterror attack.

"It's not economically viable for any company to do this kind of research because they have stockholders to think about," said Ben Neuman, a virologist at the University of Reading in Britain.

WHAT'S IN THE PIPELINE?

There are about a half dozen Ebola drugs and vaccines in development, several of which have received funding from the U.S. One drug developed by the U.S. Army has shown promising results when tested in monkeys.

"We think this may work because of the animal models but until you do the studies in humans, you just don't know," said Fred Hayden, an infectious diseases specialist at the University of Virginia, who was not involved in the research.

While animal studies for vaccine candidates have been encouraging, it's unclear what dose humans would need.

A Canadian company, Tekmira, has a $140 million contract with the U.S. government to develop a Ebola vaccine. An early test of the shot in healthy humans was stopped recently after the Food and Drug Administration asked for more safety information.

SHOULD EXPERIMENTAL DRUGS BE USED NOW?

Scientists are split on whether or not it is a good idea to try experimental drugs and vaccines before they are approved but the prospect is being informally discussed.

"Given the prolonged and unprecedented nature of the epidemic, we need to carefully consider this," said Dr. Peter Piot, the co-discoverer of Ebola in 1976 and director of the London School of Hygiene and Tropical Medicine.

The World Health Organization has no plans to facilitate any clinical trials during this outbreak, spokesman Gregory Hartl said.

Other experts say it's unethical to use treatments or vaccines that haven't been properly tested, and warn the results could be disastrous.

"None of these drugs or vaccines are ready to be used in humans from a legal point of view," said Dr. Heinz Feldmann, chief of virology at the U.S. National Institute of Allergy and Infectious Diseases.

It would be impossible to vaccinate or treat everyone in the region but if any tests do proceed, they would probably be focused on those at highest risk: health care workers.

The American woman who got the experimental drug in Liberia worked at a hospital where Ebola patients were treated. It's not known what kind of treatment she received.

If health care workers are treated, "We will have to explain why some people are getting the vaccine and others are not," Feldmann said, adding there are still vast areas of West African communities suspicious of Western aid workers and their treatments. "At the moment, it doesn't even look like the local population wants it."

___

Online:

Ebola information: http://www.who.int/csr/disease/ebola/en/



Want unlimited access to seattletimes.com? Subscribe now!

News where, when and how you want it

Email Icon

Career Center Blog

Career Center Blog

Bad email habits to break today


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►